|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:activities
|
serotonin reuptake inhibitor
|
|
gptkbp:advocates_for
|
required
|
|
gptkbp:analysis
|
statistical analysis
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
active
|
|
gptkbp:business_model
|
gptkb:software
gptkb:battle
|
|
gptkbp:class
|
indole derivatives
|
|
gptkbp:clinical_trial
|
gptkb:Alchem_Laboratories
high
Phase II
multiple sites
not yet published
|
|
gptkbp:collaborations
|
gptkb:Pharma_Corp
international study
|
|
gptkbp:collection
|
surveys
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:criteria
|
pregnant women
diagnosed with condition
|
|
gptkbp:developed_by
|
gptkb:Alchem_Laboratories
|
|
gptkbp:dosage_form
|
tablets
|
|
gptkbp:duration
|
8 weeks
|
|
gptkbp:field_of_study
|
ongoing
pharmacology
|
|
gptkbp:future_plans
|
long-term effects
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0738
|
|
gptkbp:ingredients
|
C20 H25 N3 O2
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investment
|
global
|
|
gptkbp:is_studied_in
|
randomized controlled trial
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of neurological disorders
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
2025
not yet marketed
|
|
gptkbp:participants
|
quality of life
symptom reduction
|
|
gptkbp:population
|
adults
|
|
gptkbp:products
|
IND-123456
|
|
gptkbp:publishes
|
gptkb:Journal_of_Medicinal_Chemistry
upcoming
|
|
gptkbp:receives_funding_from
|
government grant
|
|
gptkbp:regulatory_compliance
|
pending
|
|
gptkbp:research_areas
|
psychiatry
University of Medicine
|
|
gptkbp:safety_features
|
independent board
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
insomnia
dry mouth
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
serotonin receptors
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:vision
|
double-blind
|
|
gptkbp:wildlife
|
completed
|
|
gptkbp:year_created
|
gptkb:2020
|